Granulocyte colony-stimulating factors are widely used to reduce myelotoxicity of chemotherapy and to allow its regular administration. National and international guidelines regulate their use. The aim of the study was to evaluate the use of pegfilgrastim and filgrastim/lenograstim in clinical practice, adherence to ASCO and ESMO guidelines, chemotherapy-related complications and adverse reactions.

Granulocyte colony-stimulating factors used in clinical practice : PoloNord registry-based cohort Italian study / D. Fagnani, L. Isa, M.F. Verga, P. Nova, C. Casartelli, V. Filipazzi, M. Danova, G. Farina, P. Pugliese, S. Fava, A. Bertolini, C. Cimminiello, P. Boracchi, G. Marano, C. Panzarino, POLONORD Group. - In: TUMORI. - ISSN 2038-2529. - 100:5(2014), pp. 491-498.

Granulocyte colony-stimulating factors used in clinical practice : PoloNord registry-based cohort Italian study

P. Nova;V. Filipazzi;P. Boracchi;G. Marano
Penultimo
;
2014

Abstract

Granulocyte colony-stimulating factors are widely used to reduce myelotoxicity of chemotherapy and to allow its regular administration. National and international guidelines regulate their use. The aim of the study was to evaluate the use of pegfilgrastim and filgrastim/lenograstim in clinical practice, adherence to ASCO and ESMO guidelines, chemotherapy-related complications and adverse reactions.
cancer; chemotherapy-induced neutropenia; febrile neutropenia; granulocyte colony-stimulating factors
Settore MED/01 - Statistica Medica
Settore MED/06 - Oncologia Medica
2014
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/252474
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
social impact